Today, we will study why Jounce Therapeutics (JNCE) is an attractive pick in 2020.
Company overview
Jounce Therapeutics is a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapies targeting different immune cell types within the tumor microenvironment. The company is leveraging its Translational Science platform for identifying, developing, and advancing first-in-class immunotherapy programs. The company is also studying predictive biomarkers to identify the population most likely to benefit from the company’s drugs.
The company’s lead asset, vopratelimab, is a monoclonal antibody targeting ICOS (Inducible T cell CO-Stimulator), a protein on the surface of